Första AP-fonden’s Neurocrine Biosciences NBIX Stock Holding History

Första AP-fonden’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,800	Closed	-$2.81M	–	339
2025 Q4	$2.81M	Sell	19,800 -300	-1%	-$43.5K	0.02%	496
2025 Q3	$2.82M	Buy	20,100 +600	+3%	+$81.3K	0.02%	491
2025 Q2	$2.45M	Sell	19,500 -200	-1%	-$22.9K	0.02%	503
2025 Q1	$2.18M	Sell	19,700 -500	-2%	-$63.3K	0.02%	524
2024 Q4	$2.76M	Sell	20,200 -2,000	-9%	-$247K	0.02%	518
2024 Q3	$2.56M	Sell	22,200 -10,400	-32%	-$1.43M	0.02%	519
2024 Q2	$4.49M	Sell	32,600 -1,600	-5%	-$219K	0.04%	380
2024 Q1	$4.72M	Buy	34,200 +16,600	+94%	+$2.27M	0.04%	396
2023 Q4	$2.32M	Sell	17,600 -600	-3%	-$69.1K	0.02%	518
2023 Q3	$2.05M	Buy	+18,200	New	+$1.92M	0.02%	524
2022 Q4	–	Sell	-13,600	Closed	-$1.44M	–	559
2022 Q3	$1.44M	Buy	13,600 +11,000	+423%	+$1.12M	0.02%	522
2022 Q2	$253K	Buy	+2,600	New	+$240K	﹤0.01%	561
2020 Q4	–	Sell	-14,900	Closed	-$1.43M	–	538
2020 Q3	$1.43M	Buy	14,900 +2,700	+22%	+$312K	0.03%	473
2020 Q2	$1.49M	Sell	12,200 -1,600	-12%	-$177K	0.04%	447
2020 Q1	$1.19M	Buy	+13,800	New	+$1.35M	0.04%	412

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Första AP-fonden's NBIX Position: Q1 2026 in Review

Första AP-fonden sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 19,800 shares — an estimated $2.81M sold.

Första AP-fonden first reported a position in NBIX in Q1 2020 and held it in 15 quarters. The position peaked at $4.72M in Q1 2024. 700 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Första AP-fonden reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
Första AP-fonden sold 19,800 Neurocrine Biosciences shares in Q1 2026, an estimated $2.81M.
Första AP-fonden first reported a position in Neurocrine Biosciences in Q1 2020 and held it in 15 quarters.
Första AP-fonden's Neurocrine Biosciences position peaked at $4.72M in Q1 2024.
700 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Första AP-fonden's 13F filing for Q1 2026.